3 FORBES ROAD, LEXINGTON, MA
Performance-Based Stock Option Award to Garo H. Armen, CEO
Board Expansion - Marco Tullio Marcucci Appointed as Director
Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Investor Presentation
Agenus Inc. Enters Amendment to Notes and Warrants Agreement
Stockholder Votes on Director Elections and Stock Purchase Plan Amendment
Principal Accounting Officer Austin Charette Resigns Effective May 29, 2026
Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload
Automatic Shelf Registration Statement